Get started
Author

A. Gonzalez Valencia

824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)
2020 · A. Plaja Salarich, I. Teruel García, et al. · Annals of Oncology · 3
Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2024 · Beatriz Cirauqui Cirauqui, Adrià Bernat Peguera, et al. · Head & Neck · 1
PDF
281 Real-world-data on platinum outcomes after parp inhibitors progression in high grade serous ovarian cancer patients
2020 · Andrea Plaja Salarich, Iris ruel Te García, et al. · International Journal of Gynecological Cancer · 1
PDF
Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
2016 · Wael A. Harb, Alex A. Adjei, et al. · Journal of Clinical Oncology · 1
EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors
2025 · T. Moran-Bueno, A. Hernández González, et al. · Journal of Thoracic Oncology
A phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC).
2016 · Emily Chan, Wael A. Harb, et al. · Journal of Clinical Oncology
Works count: 6
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type